CONTINUATION OF OXALIPLATIN IS A POTENTIAL PREDICTIVE FACTOR IN ADJUVANT FOLFOX FOR STAGE IIIB OR IV COLORECTAL CANCER

被引：0
|
作者：
Suenaga, Mitsukuni
Mizunuma, Nobuyuki
Shinozaki, Eiji
Matsusaka, Satoshi
Chin, Keisho
Kuboki, Yasutoshi
Watanabe, Toshiyasu
Fujimoto, Yoshiya
Ueno, Masashi
Kuroyanagi, Hiroya
Oya, Masatoshi
Yamamoto, Noriko
Hatake, Kiyohiko
机构：
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [31] Oxaliplatin-Free Interval as a Risk Factor for Hypersensitivity Reaction among Colorectal Cancer Patients Treated with FOLFOX
    Mori, Yukiko
    Nishimura, Takafumi
    Kitano, Toshiyuki
    Yoshimura, Ken-ichi
    Matsumoto, Shigemi
    Kanai, Masashi
    Hazama, Megumi
    Ishiguro, Hiroshi
    Nagayama, Satoshi
    Yanagihara, Kazuhiro
    Teramukai, Satoshi
    Chiba, Tsutomu
    Sakai, Yoshiharu
    Fukushima, Masanori
    ONCOLOGY, 2010, 79 (1-2) : 136 - 143
  • [32] High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
    Yang, I-Ping
    Miao, Zhi-Feng
    Huang, Ching-Wen
    Tsai, Hsiang-Lin
    Yeh, Yung-Sung
    Su, Wei-Chih
    Chang, Tsung-Kun
    Chang, Se-fen
    Wang, Jaw-Yuan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [33] Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer
    Yusuke Okuda
    Takaya Shimura
    Tomonori Yamada
    Yoshikazu Hirata
    Ryuzo Yamaguchi
    Eiji Sakamoto
    Hiromi Kataoka
    International Journal of Clinical Oncology, 2018, 23 : 1101 - 1111
  • [34] Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer
    Okuda, Yusuke
    Shimura, Takaya
    Yamada, Tomonori
    Hirata, Yoshikazu
    Yamaguchi, Ryuzo
    Sakamoto, Eiji
    Kataoka, Hiromi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (06) : 1101 - 1111
  • [35] Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)
    Kotaka, Masahito
    Iwamoto, Shigeyoshi
    Satake, Hironaga
    Sakai, Daisuke
    Kudo, Toshihiro
    Fukunaga, Mutsumi
    Konishi, Ken
    Ide, Yoshihito
    Ikumoto, Taro
    Tsuji, Akihito
    Sano, Yasushi
    Kato, Takeshi
    Sugimoto, Naotoshi
    Satoh, Taroh
    Kanazawa, Akiyoshi
    Kurata, Takayasu
    Yamanaka, Takeharu
    Tomita, Naohiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (08) : 1515 - 1522
  • [36] Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)
    Masahito Kotaka
    Shigeyoshi Iwamoto
    Hironaga Satake
    Daisuke Sakai
    Toshihiro Kudo
    Mutsumi Fukunaga
    Ken Konishi
    Yoshihito Ide
    Taro Ikumoto
    Akihito Tsuji
    Yasushi Sano
    Takeshi Kato
    Naotoshi Sugimoto
    Taroh Satoh
    Akiyoshi Kanazawa
    Takayasu Kurata
    Takeharu Yamanaka
    Naohiro Tomita
    International Journal of Clinical Oncology, 2020, 25 : 1515 - 1522
  • [37] Is tumor microsatellite-instability status a predictive factor for FOLFOX treatment in metastatic colorectal cancer?
    Des Guetz, Gaetan
    Schischmanoff, Olivier
    Chouahnia, Kader
    Cornelis, Francxois
    Lagorce, Christine
    Wind, Philippe
    Benamouzig, Robert
    Morere, Jean-Francois
    Benichou, Joseph
    Breau, Jean-Luc
    ANNALS OF ONCOLOGY, 2006, 17 : 248 - 248
  • [38] DcR3 is a predictive factor in the adjuvant treatment of colorectal cancer.
    Rochlitz, C
    Boulay, JL
    Mild, G
    Reuter, J
    Terracciano, L
    Gudat, F
    Metzger, U
    Laffer, U
    Lowy, A
    Stamm, B
    Herrmann, R
    ANNALS OF ONCOLOGY, 2000, 11 : 59 - 59
  • [39] Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin
    Nagourney, Robert A.
    Evans, Steven
    Tran, Peter H.
    Nagourney, Adam J.
    Sugarbaker, Paul H.
    EJSO, 2021, 47 (04): : 738 - 742
  • [40] C-Reactive Protein Is a Negative Independent Factor in Patients with Stage IV Colorectal Cancer Undergoing Oxaliplatin-based Chemotherapy
    Fukuchi, Minoru
    Kuwabara, Kohki
    Tsuji, Yoshitaka
    Baba, Hiroyuki
    Ishibashi, Keiichiro
    Chika, Noriyasu
    Hatano, Satoshi
    Matsuzawa, Takeaki
    Kumamoto, Kensuke
    Kumagai, Youichi
    Mochiki, Erito
    Ishida, Hideyuki
    ANTICANCER RESEARCH, 2013, 33 (11) : 5051 - 5055
12345